Payment overview · 2025
General Payments
$22.25
1 reported records · 1 companies
Healthcare provider profile · identity verified
Michael Jon Beste, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MELROSE, MN · NPI 1700220712
Verified facts
What the public records show
CMS Open Payments records show Michael Jon Beste, M.D. received $22.25 in general payments during 2025 across 1 reported records.
KARL STORZ Endoscopy-America accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| KARL STORZ Endoscopy-America | Unresolved — no canonical attribution shown | $22.25 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $22.25 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 759 | 195 |
| Lisinopril | Lisinopril | 481 | 119 |
| Gabapentin | Gabapentin | 312 | 58 |
| Losartan Potassium | Losartan Potassium | 299 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 289 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 74 |
| Omeprazole | Omeprazole | 265 | 74 |
| Furosemide | Furosemide | 231 | 66 |
| Simvastatin | Simvastatin | 226 | 51 |
| Metformin Hcl | Metformin Hcl | 216 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 206 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 186 | 37 |
| Allopurinol | Allopurinol | 170 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 31 |
| Eliquis | Apixaban | 131 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 125 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 40 |
| Xarelto | Rivaroxaban | 101 | 16 |
| Potassium Chloride | Potassium Chloride | 95 | 26 |
| Atenolol | Atenolol | 91 | 22 |
| Tramadol Hcl | Tramadol Hcl | 86 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 24 |
| Metformin Hcl Er | Metformin Hcl | 80 | 20 |
| Mirtazapine | Mirtazapine | 74 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 15 |
| Trazodone Hcl | Trazodone Hcl | 65 | 14 |
| Ozempic | Semaglutide | 62 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 62 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Glimepiride | Glimepiride | 61 | 11 |
| Sertraline Hcl | Sertraline Hcl | 60 | 16 |
| Jardiance | Empagliflozin | 56 | 11 |
| Carvedilol | Carvedilol | 54 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 16 |
| Finasteride | Finasteride | 54 | 18 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 50 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 12 |
| Famotidine | Famotidine | 48 | 16 |
| Glipizide Er | Glipizide | 48 | 15 |
| Amoxicillin | Amoxicillin | 47 | 31 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Torsemide | Torsemide | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 23 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 23 |
| Prednisone | Prednisone | 31 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Cephalexin | Cephalexin | 27 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $22.25 · 1 records | KARL STORZ Endoscopy-America | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error